Henry Waxman is a household name in pharmaceutical circles — during his three decades on Capitol Hill, he helped write the Affordable Care Act and expand Medicaid and the Children’s Health Insurance Program. He sponsored the 1984 Hatch-Waxman Act, which set up the modern infrastructure for bringing generic drugs to market, and chaired the Energy and Commerce Committee, which has jurisdiction over health-related issues, from 2009 to 2011.
Since his retirement from Congress in 2015, Waxman has served as chairman of Waxman Strategies, a lobbying firm that has been active on health issues, especially the 340B drug discount program.
STAT recently sat down with Waxman to hear his thoughts on the current political landscape around drug pricing, and what his prescription is for change.
